- What other names is 5-htp known by?
- What is 5-htp?
- How does 5-htp work?
- Are there safety concerns?
- Are there any interactions with medications?
- Dosing considerations for 5-htp.
2-Amino-3-(5-Hydroxy-1H-Indol-3-yl)Propanoic Acid, 5 Hydroxy-Tryptophan, 5 Hydroxy-Tryptophane, 5-Hydroxytryptophan, 5-Hydroxytryptophane, 5-Hydroxy L-Tryptophan, 5-Hydroxy L-Tryptophane, 5-Hydroxy Tryptophan, 5-L-Hydroxytryptophan, L-5 HTP, L-5-Hydroxytryptophan, L-5-Hydroxytryptophane, Oxitriptan.
5-HTP (5-Hydroxytryptophan) is a chemical by-product of the protein building block L-tryptophan. It is also produced commercially from the seeds of an African plant known as Griffonia simplicifolia 5-HTP is used for sleep disorders such as insomnia, depression, anxiety, migraine and tension-type headaches, fibromyalgia, obesity, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), attention deficit-hyperactivity disorder (ADHD), seizure disorder, and Parkinson's disease..
Possibly Effective for...
- Depression. Some clinical research shows that taking 5-HTP by mouth improve symptoms of depression in some people. Some clinical research shows that taking 5-HTP by mouth might be as beneficial as certain prescription antidepressant drugs for improving depression symptoms. In most studies, 150-800 mg daily of 5-HTP was taken. In some cases, higher doses have been used.
Possibly Ineffective for...
- Down syndrome. Some research shows that giving 5-HTP to infants with Down syndrome might improve muscle and activity. Other research shows that it does not improve muscle or development when taken from infancy until 3-4 years of age. Research also shows that taking 5-HTP along with conventional prescription drugs does improve development, social skills, or language skills.
Insufficient Evidence to Rate Effectiveness for...
- Alcoholism. Early research shows that taking 5-HTP with D-phenylalanine and L-glutamine for 40 days can reduce alcohol withdrawal symptoms. However, taking 5-HTP with carbidopa daily for one year does not seem to help people stop drinking. The effect of 5-HTP alone for alcoholism is not clear.
- Alzheimer's disease. Early research suggests that taking 5-HTP by mouth does not help symptoms of Alzheimer's disease.
- Anxiety. Evidence on the effects of 5-HTP for anxiety is unclear. Early research shows that taking 25-150 mg of 5-HTP by mouth daily along with carbidopa seems to reduce anxiety symptoms in people with anxiety disorders. However, other early research shows that taking higher doses of 5-HTP, 225 mg daily or more, seems to make anxiety worse. Also, taking 60 mg of 5-HTP daily through the vein does not reduce anxiety in people with panic disorders.
- Nervous system disorder (Cerebellar ataxia). Evidence on the use of 5-HTP for cerebellar ataxia is unclear. Early evidence shows that taking 5 mg/kg of 5-HTP daily for 4 months can decrease nervous system dysfunction. However, other research shows that taking 5-HTP daily for up to one year does not improve symptoms of cerebellar ataxia.
- Fibromyalgia. Early research suggests that taking 100 mg of 5-HTP by mouth three times daily for 30-90 days might improve pain, tenderness, sleep, anxiety, fatigue, and morning stiffness in people with fibromyalgia.
- Menopausal symptoms. Early research suggests that taking 150 mg of 5-HTP daily for 4 weeks does not reduce hot flashes in postmenopausal women.
- Migraine headache. Evidence on the effects of 5-HTP for the prevention or treatment of migraines in adults is unclear. Some studies show that taking 5-HTP daily does not reduce migraines, while other studies show that it might be as beneficial as prescription drugs. 5-HTP does not seem to reduce migraines in children.
- Obesity. Early research suggests that taking 5-HTP might help reduce appetite, caloric intake, and weight in obese people. Other research suggests that using a specific mouth spray containing 5-HTP and other extracts (5-HTP-Nat Exts, Medestea Biotech S.p.a., Torino, Italy) for 4 weeks increases weight loss by about 41% in overweight postmenopausal women.
- Parkinson's disease. Early research shows that taking 100-150 mg of 5-HTP by mouth daily with conventional drugs seems to reduce shaking, but these benefits only continue for up to 5 months. Taking larger doses of 5-HTP, 275-1500 mg daily along with carbidopa seems to worsen symptoms.
- Schizophrenia. Early research suggests that taking 800 mg to 6 grams of 5-HTP daily with carbidopa for 90 days might improve schizophrenia symptoms in some young men.
- Tension headache. Early research suggests that taking 100 mg of 5-HTP three times daily for 8 weeks does not reduce pain or the length of tension headaches.
- Heroin withdrawal symptoms. Early research suggests that taking 200 mg of 5-HTP daily for 6 days together with tyrosine, phosphatidylcholine, and L-glutamine, might reduce insomnia and withdrawal symptoms in recovering heroin addicts.
- Attention deficit-hyperactivity disorder (ADHD).
- Premenstrual dysphoric disorder (PMDD).
- Premenstrual syndrome (PMS).
- Ramsey-Hunt syndrome.
- Other conditions.
5-HTP works in the brain and central nervous system by increasing the production of the chemical serotonin. Serotonin can affect sleep, appetite, temperature, sexual behavior, and pain sensation. Since 5-HTP increases the synthesis of serotonin, it is used for several diseases where serotonin is believed to play an important role including depression, insomnia, obesity, and many other conditions.
5-HTP is POSSIBLY SAFE when taking by mouth appropriately. 5-HTP has been used safely in doses up to 400 mg daily for up to one year. However, some people who have taken it have developed a condition called eosinophilia-myalgia syndrome (EMS), a serious condition involving extreme muscle tenderness (myalgia) and blood abnormalities (eosinophilia). Some people think EMS might be caused by an accidental ingredient or contaminant in some 5-HTP products. However, there is not enough scientific evidence to know if EMS is caused by 5-HTP, a contaminant, or some other factor. Until more is known, 5-HTP should be used cautiously.
5-HTP is POSSIBLY UNSAFE when taken by mouth in large doses. Doses from 6-10 grams daily have been linked to severe stomach problems and muscle spasms.
Special Precautions & Warnings:Children: 5-HTP is POSSIBLY SAFE when taken by mouth appropriately. Doses of up to 5 mg/kg daily have been used safely for up to 3 years in infants and children up to 12 years-old. As with adults, there is also concern about the potential for eosinophilia-myalgia syndrome (EMS) in children, a serious condition involving extreme muscle tenderness (myalgia) and blood abnormalities (eosinophilia).
Surgery: 5-HTP can affect a brain chemical called serotonin. Some drugs administered during surgery can also affect serotonin. Taking 5-HTP before surgery might cause too much serotonin in the brain and can result in serious side effects including heart problems, shivering, and anxiety. Tell patients to stop taking 5-HTP at least 2 weeks before surgery.
Medications for depression (Antidepressant drugs)Interaction Rating: Major Do not take this combination.
5-HTP increases a brain chemical called serotonin. Some medications for depression also increase serotonin. Taking 5-HTP along with these medications for depression might increase serotonin too much and cause serious side effects including heart problems, shivering, and anxiety. Do not take 5-HTP if you are taking medications for depression.
Medications for depression (MAOIs)Interaction Rating: Major Do not take this combination.
5-HTP increases a chemical in the brain. This chemical is called serotonin. Some medications used for depression also increase serotonin. Taking 5-HTP with these medications used for depression might cause there to be too much serotonin. This could cause serious side effects including heart problems, shivering, and anxiety.
Some of these medications used for depression include phenelzine (Nardil), tranylcypromine (Parnate), and others.
Carbidopa (Lodosyn)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
5-HTP can affect the brain. Carbidopa (Lodosyn) can also affect the brain. Taking 5-HTP along with carbidopa can increase the risk of serious side effects including rapid speech, anxiety, aggressiveness, and others.
Dextromethorphan (Robitussin DM, and others)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
5-HTP can affect a brain chemical called serotonin. Dextromethorphan (Robitussin DM, others) can also affect serotonin. Taking 5-HTP along with dextromethorphan (Robitussin DM, others) might cause too much serotonin in the brain and can result in serious side effects including heart problems, shivering, and anxiety. Do not take 5-HTP if you are taking dextromethorphan (Robitussin DM, and others).
Meperidine (Demerol)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
5-HTP increases a chemical in the brain called serotonin. Meperidine (Demerol) can also increase serotonin in the brain. Taking 5-HTP along with meperidine (Demerol) might cause too much serotonin in the brain and serious side effects including heart problems, shivering, and anxiety.
Pentazocine (Talwin)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
5-HTP increases a brain chemical called serotonin. Pentazocine (Talwin) also increases serotonin. Taking 5-HTP along with pentazocine (Talwin) might increase serotonin too much. This might cause serious side effects including heart problems, shivering, and anxiety. Do not take 5-HTP if you are taking pentazocine (Talwin).
Sedative medications (CNS depressants)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
5-HTP might cause sleepiness and drowsiness. Medications that cause sleepiness are called sedatives. Taking 5-HTP along with sedative medications might cause too much sleepiness.
Tramadol (Ultram)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
5-HTP increases a brain chemical called serotonin. Tramadol (Ultram) can also increase serotonin. Taking 5-HTP along with tramadol (Ultram) might cause too much serotonin in the brain and might result in side effects including confusion, shivering, stiff muscles, and others.
The following doses have been studied in scientific research:
- For depression: Most commonly, 150-800 mg daily is taken for 2-6 weeks. These doses are sometimes divided up and administered as 50 mg to 100 mg three times a day. Sometimes the dose starts out low and steadily increases every 1-2 weeks until a target dose is reached. Less commonly, higher doses are used. In one study, the dose is steadily increased up to 3 grams per day.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors
Adamsen, D., Meili, D., Blau, N., Thony, B., and Ramaekers, V. Autism associated with low 5-hydroxyindolacetic acid in CSF and the heterozygous SLC6A4 gene Gly56Ala plus 5-HTTLPR L/L promoter variants. Mol.Genet.Metab 2011;102(3):368-373. View abstract.
Alino, J. J., Gutierrez, J. L., and Iglesias, M. L. 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study. Int Pharmacopsychiatry 1976;11(1):8-15. View abstract.
Anders, T. F., Cann, H. M., Ciaranello, R. D., Barchas, J. D., and Berger, P. A. Further observations on the use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome. Neuropadiatrie. 1978;9(2):157-166. View abstract.
Anderson, L. T., Herrmann, L., and Dancis, J. The effect of L-5-hydroxytryptophan on self-mutilatin in Lesch-Nyhan disease: a negative report. Neuropadiatrie. 1976;7(4):439-442. View abstract.
Auffret, M., Comte, H., and Bene, J. Eosinophilia-myalgia syndrome induced by L-5 hydroxytryptophane: about three cases. Fund Clin Pharmacol 2013;Suppl 1(120):poster P2-204.
Bainbridge, M. N., Wiszniewski, W., Murdock, D. R., Friedman, J., Gonzaga-Jauregui, C., Newsham, I., Reid, J. G., Fink, J. K., Morgan, M. B., Gingras, M. C., Muzny, D. M., Hoang, L. D., Yousaf, S., Lupski, J. R., and Gibbs, R. A. Whole-genome sequencing for optimized patient management. Sci Transl.Med 6-15-2011;3(87):87re3. View abstract.
Baraldi, S., Hepgul, N., Mondelli, V., and Pariante, C. M. Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol. 2012;32(4):531-543. View abstract.
Bastard, J., Truelle, J. L., and Emile, J. [Effectiveness of 5 hydroxy-tryptophan in Parkinson's disease]. Nouv Presse Med 9-11-1976;5(29):1836-1837. View abstract.
Bono, G., Micieli, G., Sances, G., Calvani, M., and Nappi, G. L-5HTP treatment in primary headaches: an attempt at clinical identification of responsive patients. Cephalalgia 1984;4(3):159-165. View abstract.
Brodie HKH, Sack R, and Siever L. Clinical studies of L-5-hydroxytryptophan in depression. In: Barchas J and Usdin E. Serotonin and behavior. New York: Academic Press;1973.
Chadwick, D., Hallett, M., Harris, R., Jenner, P., Reynolds, E. H., and Marsden, C. D. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain 1977;100(3):455-487. View abstract.
Chae, H. S., Kang, O. H., Choi, J. G., Oh, Y. C., Lee, Y. S., Jang, H. J., Kim, J. H., Park, H., Jung, K. Y., Sohn, D. H., and Kwon, D. Y. 5-hydroxytryptophan acts on the mitogen-activated protein kinase extracellular-signal regulated protein kinase pathway to modulate cyclooxygenase-2 and inducible nitric oxide synthase expression in RAW 264.7 cells. Biol Pharm Bull 2009;32(4):553-557. View abstract.
Chase, T. N., Ng, L. K., and Watanabe, A. M. Parkinson's disease. Modification by 5-hydroxytryptophan. Neurology 1972;22(5):479-484. View abstract.
Ciaranello, R. D., Anders, T. F., Barchas, J. D., Berger, P. A., and Cann, H. M. The use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome. Child Psychiatry Hum Dev 1976;7(2):127-133. View abstract.
Cross, D. R., Kellermann, G., McKenzie, L. B., Purvis, K. B., Hill, G. J., and Huisman, H. A randomized targeted amino acid therapy with behaviourally at-risk adopted children. Child Care Health Dev. 2011;37(5):671-678. View abstract.
Curcio, J. J., Kim, L. S., Wollner, D., and Pockaj, B. A. The potential of 5-hydryoxytryptophan for hot flash reduction: a hypothesis. Altern Med Rev 2005;10(3):216-221. View abstract.
Dill, P., Wagner, M., Somerville, A., Thony, B., Blau, N., and Weber, P. Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency. Neurology 1-31-2012;78(5):e29-e32. View abstract.
Friedman, J., Roze, E., Abdenur, J. E., Chang, R., Gasperini, S., Saletti, V., Wali, G. M., Eiroa, H., Neville, B., Felice, A., Parascandalo, R., Zafeiriou, D. I., Arrabal-Fernandez, L., Dill, P., Eichler, F. S., Echenne, B., Gutierrez-Solana, L. G., Hoffmann, G. F., Hyland, K., Kusmierska, K., Tijssen, M. A., Lutz, T., Mazzuca, M., Penzien, J., Poll-The BT, Sykut-Cegielska, J., Szymanska, K., Thony, B., and Blau, N. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol. 2012;71(4):520-530. View abstract.
Frith, C. D., Johnston, E. C., Joseph, M. H., Powell, R. J., and Watts, R. W. Double-blind clinical trial of 5-hydroxytryptophan in a case of Lesch- Nyhan syndrome. J Neurol Neurosurg.Psychiatry 1976;39(7):656-662. View abstract.
Gendle, M. H. and Golding, A. C. Oral administration of 5-hydroxytryptophan (5-HTP) impairs decision making under ambiguity but not under risk: evidence from the Iowa Gambling Task. Hum Psychopharmacol. 2010;25(6):491-499. View abstract.
Growdon, J. H., Young, R. R., and Shahani, B. T. L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent. Neurology 1976;26(12):1135-1140. View abstract.
Halladay, A. K., Wagner, G. C., Sekowski, A., Rothman, R. B., Baumann, M. H., and Fisher, H. Alterations in alcohol consumption, withdrawal seizures, and monoamine transmission in rats treated with phentermine and 5-hydroxy-L-tryptophan. Synapse 2006;59(5):277-289. View abstract.
Hendricks, E. J., Rothman, R. B., and Greenway, F. L. How physician obesity specialists use drugs to treat obesity. Obesity.(Silver.Spring) 2009;17(9):1730-1735. View abstract.
Horvath, G. A., Selby, K., Poskitt, K., Hyland, K., Waters, P. J., Coulter-Mackie, M., and Stockler-Ipsiroglu, S. G. Hemiplegic migraine, seizures, progressive spastic paraparesis, mood disorder, and coma in siblings with low systemic serotonin. Cephalalgia 2011;31(15):1580-1586. View abstract.
Horvath, G. A., Stockler-Ipsiroglu, S. G., Salvarinova-Zivkovic, R., Lillquist, Y. P., Connolly, M., Hyland, K., Blau, N., Rupar, T., and Waters, P. J. Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: evidence of a phenotypic continuum between dominant and recessive forms. Mol.Genet.Metab 2008;94(1):127-131. View abstract.
Iovieno, N., Dalton, E. D., Fava, M., and Mischoulon, D. Second-tier natural antidepressants: review and critique. J Affect.Disord. 2011;130(3):343-357. View abstract.
Irwin, M. R., Marder, S. R., Fuentenebro, F., and Yuwiler, A. L-5-hydroxytryptophan attenuates positive psychotic symptoms induced by D-amphetamine. Psychiatry Res. 1987;22(4):283-289. View abstract.
Jacobsen, J. P., Nielsen, E. O., Hummel, R., Redrobe, J. P., Mirza, N., and Weikop, P. Insensitivity of NMRI mice to selective serotonin reuptake inhibitors in the tail suspension test can be reversed by co-treatment with 5-hydroxytryptophan. Psychopharmacology (Berl) 2008;199(2):137-150. View abstract.
Ju, C. Y. and Tsai, C. T. Serotonergic mechanisms involved in the suppression of feeding by 5-HTP in rats. Chin J Physiol 1995;38(4):235-240. View abstract.
Klein P, Lees A, and Stern G. Consequences of chronic 5-hydroxytryptophan in parkinsonian instability of gait and balance and in other neurological disorders. Adv Neurol 1986;45:603-604.
Lesch, K. P., Hoh, A., Disselkamp-Tietze, J., Wiesmann, M., Osterheider, M., and Schulte, H. M. 5-Hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls. Arch Gen Psychiatry 1991;48(6):540-547. View abstract.
Leu-Semenescu, S., Arnulf, I., Decaix, C., Moussa, F., Clot, F., Boniol, C., Touitou, Y., Levy, R., Vidailhet, M., and Roze, E. Sleep and rhythm consequences of a genetically induced loss of serotonin. Sleep 3-1-2010;33(3):307-314. View abstract.
Liu, K. M., Liu, T. T., Lee, N. C., Cheng, L. Y., Hsiao, K. J., and Niu, D. M. Long-term follow-up of Taiwanese Chinese patients treated early for 6-pyruvoyl-tetrahydropterin synthase deficiency. Arch Neurol. 2008;65(3):387-392. View abstract.
Longo, N. Disorders of biopterin metabolism. J Inherit.Metab Dis 2009;32(3):333-342. View abstract.
Magnussen, I. and Nielsen-Kudsk, F. Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state. Acta Pharmacol Toxicol.(Copenh) 1980;46(4):257-262. View abstract.
Mathew NT. 5-hydroxytryptophan in the prophylaxis of migraine: a double-blind study. Headache 1978;18:111.
Meolie, A. L., Rosen, C., Kristo, D., Kohrman, M., Gooneratne, N., Aguillard, R. N., Fayle, R., Troell, R., Townsend, D., Claman, D., Hoban, T., and Mahowald, M. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin.Sleep Med 4-15-2005;1(2):173-187. View abstract.
Morrison, K. E. Whole-genome sequencing informs treatment: personalized medicine takes another step forward. Clin Chem 2011;57(12):1638-1640. View abstract.
Morrow, J. D., Vikraman, S., Imeri, L., and Opp, M. R. Effects of serotonergic activation by 5-hydroxytryptophan on sleep and body temperature of C57BL/6J and interleukin-6-deficient mice are dose and time related. Sleep 1-1-2008;31(1):21-33. View abstract.
Nolen, W. A., van de Putte, J. J., Dijken, W. A., Kamp, J. S., Blansjaar, B. A., Kramer, H. J., and Haffmans, J. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr.Scand 1988;78(6):676-683. View abstract.
Opladen, T., Hoffmann, G. F., and Blau, N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit.Metab Dis 2012;35(6):963-973. View abstract.
Pan, L., McKain, B. W., Madan-Khetarpal, S., Mcguire, M., Diler, R. S., Perel, J. M., Vockley, J., and Brent, D. A. GTP-cyclohydrolase deficiency responsive to sapropterin and 5-HTP supplementation: relief of treatment-refractory depression and suicidal behaviour. BMJ Case.Rep. 2011;2011 View abstract.
Petre-Quadens, O. and De Lee, C. 5-Hydroxytryptophan and sleep in Down's syndrome. J Neurol Sci 1975;26(3):443-453. View abstract.
Pons, R. The phenotypic spectrum of paediatric neurotransmitter diseases and infantile parkinsonism. J Inherit.Metab Dis 2009;32(3):321-332. View abstract.
Pranzatelli, M. R., Tate, E., Galvan, I., and Wheeler, A. A controlled trial of 5-hydroxy-L-tryptophan for ataxia in progressive myoclonus epilepsy. Clin Neurol.Neurosurg. 1996;98(2):161-164. View abstract.
Pranzatelli, M. R., Tate, E., Huang, Y., Haas, R. H., Bodensteiner, J., Ashwal, S., and Franz, D. Neuropharmacology of progressive myoclonus epilepsy: response to 5- hydroxy-L-tryptophan. Epilepsia 1995;36(8):783-791. View abstract.
Quadbeck, H., Lehmann, E., and Tegeler, J. Comparison of the antidepressant action of tryptophan, tryptophan/5- hydroxytryptophan combination and nomifensine. Neuropsychobiology 1984;11(2):111-115. View abstract.
Rosano Burgio, F., Borgatti, R., Scarabello, E., and Lanzi, G. Headache in children and adolescents. Proceedings of the First International Symposium on Headache in Children and Adolecents. 1989;339-47.
Rothman, R. B. Treatment of obesity with "combination" pharmacotherapy. Am J Ther 2010;17(6):596-603. View abstract.
Sano I. Therapy of depression with L-5-hydroxytryptophan (L-5-HTP). Psychiatria et Neurologia Japonicas 1972;74:584.
Sarris, J. Clinical depression: an evidence-based integrative complementary medicine treatment model. Altern.Ther.Health Med. 2011;17(4):26-37. View abstract.
Schaefer, M., Winterer, J., Sarkar, R., Uebelhack, R., Franke, L., Heinz, A., and Friebe, A. Three cases of successful tryptophan add-on or monotherapy of hepatitis C and IFNalpha-associated mood disorders. Psychosomatics 2008;49(5):442-446. View abstract.
Shaw, K., Turner, J., and Del Mar, C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database.Syst Rev 2002;(1):CD003198. View abstract.
Soulairac, A. [Hypnotic action of mecloqualone. Comparison with placebo effects and secobarbital]. Presse Med 4-10-1971;79(18):817-818. View abstract.
Thal, L. J., Sharpless, N. S., Wolfson, L., and Katzman, R. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations. Ann Neurol 1980;7(6):570-576. View abstract.
Thomson, J., Rankin, H., Ashcroft, G. W., Yates, C. M., McQueen, J. K., and Cummings, S. W. The treatment of depression in general practice: a comparison of L- tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychol Med 1982;12(4):741-751. View abstract.
Trouillas P. Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination of 5-HTP-benserazide: 21 cases with quantified symptoms processed by computer. Ital J Neurol Sci 1984;5(3):253-266. View abstract.
Trouillas, P., Garde, A., Robert, J. M., and Adeleine, P. [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan]. C.R.Seances Acad Sci III 1-5-1981;292(1):119-122. View abstract.
Trouillas, P., Garde, A., Robert, J. M., Renaud, B., Adeleine, P., Bard, J., and Brudon, F. [Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods]. Rev Neurol.(Paris) 1982;138(5):415-435. View abstract.
Trujillo-Martin, M. M., Serrano-Aguilar, P., Monton-Alvarez, F., and Carrillo-Fumero, R. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord. 6-15-2009;24(8):1111-1124. View abstract.
van Praag, H. and de Hann, S. Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res. 1980;3(1):75-83. View abstract.
van Praag, H. M. and de Haan, S. Chemoprophylaxis of depressions. An attempt to compare lithium with 5- hydroxytryptophan. Acta Psychiatr.Scand Suppl 1981;290:191-201. View abstract.
van Praag, H. M. In search of the mode of action of antidepressants: 5-HTP/tyrosine mixtures in depression. Adv Biochem Psychopharmacol. 1984;39:301-314. View abstract.
Van Woert, M. H., Rosenbaum, D., Howieson, J., and Bowers, M. B., Jr. Long-term therapy of myoclonus and other neurologic disorders with L-5- hydroxytryptophan and carbidopa. N Engl J Med 1-13-1977;296(2):70-75. View abstract.
VanPraag, H. M. and Korf, J. 5-Hydroxytryptophan as antidepressant: The predictive value of the probenecid test. Psychopharmacol.Bull. 1972;8(4):34-35.
Victor, S. and Ryan, S. W. Drugs for preventing migraine headaches in children. Cochrane Database.Syst.Rev 2003;(4):CD002761. View abstract.
Weeks, B. S. Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action: Relarian. Med Sci Monit. 2009;15(11):RA256-RA262. View abstract.
Wyatt, R. J., Vaughan, T., Galanter, M., Kaplan, J., and Green, R. Behavioral changes of chronic schizophrenic patients given L-5- hydroxytryptophan. Science 9-22-1972;177(54):1124-1126. View abstract.
Wyatt, R. J., Vaughan, T., Kaplan, J., Galanter, M., and Green, R. 5-Hydroxytryptophan and chronic schizophrenia. In: Barchas J and Usdin E. Serotonin and Behavior. New York: Acedemic Press;1973.
Zarcone, V. P., Jr. and Hoddes, E. Effects of 5-hydroxytryptophan on fragmentation of REM sleep in alcoholics. Am J Psychiatry 1975;132(1):74-76. View abstract.
Zarcone, V., Kales, A., Scharf, M., Tan, T. L., Simmons, J. Q., and Dement, W. C. Repeated oral ingestion of 5-hydroxytryptophan. The effect on behavior and sleep processes in two schizophrenic children. Arch Gen Psychiatry 1973;28(6):843-846. View abstract.
Zmilacher, K., Battegay, R., and Gastpar, M. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology 1988;20(1):28-35. View abstract.
Angst J, Woggon B, Schoepf J. The treatment of depression with L-5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study. Arch Psychiatr Nervenkr 1977;224:175-86. View abstract.
Bazelon M, Paine RS, Cowie VA, et al. Reversal of hypotonia in infants with Down's syndrome by administration of 5-hydroxytryptophan. Lancet 1967;1:1130-3. View abstract.
Birdsall TC. 5-Hydroxytryptophan: A Clinically-Effective Serotonin Precursor. Altern Med Rev 1998;3:271-80. View abstract.
Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol 1987;7:127-37.. View abstract.
Cangiano C, Ceci F, Cairella M, et al. Effects of 5-hydroxytryptophan on eating behavior and adherence to dietary prescriptions in obese adult subjects. Adv Exp Med Biol 1991;294:591-3. View abstract.
Cangiano C, Ceci F, Cancino A, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr 1992;56:863-7. View abstract.
Cangiano C, Laviano A, Del Ben M, et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. Int J Obes Relat Metab Disord 1998;22:648-54. View abstract.
Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990;18:201-9. View abstract.
Ceci F, Cangiano C, Cairella M, et al. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. J Neural Transm 1989;76:109-17. View abstract.
Chen D, Liu Y, He W, Wang H, Wang Z. Neurotransmitter-precursor-supplement intervention for detoxified heroin addicts. J Huazhong Univ Sci Technolog Med Sci 2012;32(3):422-7.
Das YT, Bagchi M, Bagchi D, Preuss HG. Safety of 5-hydroxy-L-tryptophan. Toxicol Lett 2004;150:111-22. View abstract.
De Benedittis G, Massei R. 5-HT precursors in migraine prophylaxis: a double-blind cross-over study with L-5-hydroxytryptophan. Clin J Pain 1986;2:123-129.
De Benedittis G, Massei R. Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. J Neurosurg Sci 1985;29:239-48. View abstract.
De Giorgis G, Miletto R, Iannuccelli M, Camuffo M, Scerni S. Headache in association with sleep disorders in children: a psychodiagnostic evaluation and controlled clinical study--L-5-HTP versus placebo. Drugs Exp Clin Res 1987;13:425-33. View abstract.
den Boer JA, Westenberg HG. Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res 1990;31:267-78. View abstract.
Freedman RR. Treatment of menopausal hot flashes with 5-hydroxytryptophan. Maturitas 2010;65:383-5. View abstract.
Gendle MH, Young EL, Romano AC. Effects of oral 5-hydroxytryptophan on a standardized planning task: insight into possible dopamine/serotonin interactions in the forebrain. Hum Psychopharmacol 2013;28(3):270-3.
George DT, Lindquist T, Rawlings RR, et al. Pharmacologic maintenance of abstinence in patients with alcoholism: no efficacy of 5-hydroxytryptophan or levodopa. Clin Pharmacol Ther 1992;52:553-60. View abstract.
Jangid P, Malik P, Singh P, Sharma M, Gulia AK. Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode. Asian J Psychiatr 2013;6:29-34. View abstract.
Johnson KL, Klarskov K, Benson LM, et al. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. J Rheumatol 1999;26:2714-7. View abstract.
Jukic T, Rojc B, Boben-Bardutzky D, Hafner M, Ihan A. The use of a food supplementation with D-phenylalanine, L-glutamine and L-5-hydroxytriptophan in the alleviation of alcohol withdrawal symptoms. Coll Antropol 2011;35:1225-30. View abstract.
Kahn RS, Westenberg HG, Verhoeven WM, et al. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 1987;21:33-45. View abstract.
Kahn RS, Westenberg HG. L-5-hydroxytryptophan in the treatment of anxiety disorders. J Affect Disord 1985;8:197-200. View abstract.
Kaneko M, Kumashiro H, Takahashi Y, Hoshino Y. L-5HTP treatment and serum 5-HT level after L-5-HTP loading on depressed patients. Neuropsychobiology 1979;5:232-40. View abstract.
Lemaire PA, Adosraku RK. An HPLC method for the direct assay of the serotonin precursor, 5-hydroxytrophan, in seeds of Griffonia simplicifolia. Phytochem Anal 2002;13(6):333-7.View abstract.
Longo G, Rudoi I, Iannuccelli M, Strinati R, Panizon F. [Treatment of essential headache in developmental age with L-5-HTP (cross over double-blind study versus placebo)]. Pediatr Med Chir 1984;6:241-5. View abstract.
Maissen CP, Ludin HP. [Comparison of the effect of 5-hydroxytryptophan and propranolol in the interval treatment of migraine]. Schweiz Med Wochenschr 1991;121:1585-90. View abstract.
Meyer JS, Welch KM, Deshmukh VD, et al. Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer's disease. J Amer Geriat Soc 1977;25:289-98. View abstract.
Michelson D, Page SW, Casey R, et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J Rheumatol 1994;21:2261-5. View abstract.
Michelson D, Page SW, Casey R, et al. An eosinophilia-myaligia syndrome related disorder associated with exposure to l-5-hydroxytryptophan. J Rheumatol 1994;21(12):2261-5. View abstract.
Nakajima T, Kudo Y, Kaneko Z. Clinical evaluation of 5-hydroxy-L-tryptophan as an antidepressant drug. Folia Psychiatr Neurol Jpn 1978;32:223-30. View abstract.
Nardini M, De Stefano R, Iannuccelli M, et al. Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study. Int J Clin Pharmacol Res 1983;3:239-50. View abstract.
Nolen WA, van de Putte JJ, Dijken WA, Kamp JS. L-5HTP in depression resistant to re-uptake inhibitors. An open comparative study with tranylcypromine. Br J Psychiatry 1985;147:16-22. View abstract.
Pardo JV. Mania following addition of hydroxytryptophan to monoamine oxidase inhibitor. Gen Hosp Psychiatry 2012;34(1):102.e13-4.
Poldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. Psychopathology 1991;24:53-81. View abstract.
Preshaw RM, Leavitt D, Hoag G. The dietary supplement 5-hydroxytryptophan and urinary 5-hydroxyindole acetic acid. CMAJ 2008;178:993. View abstract.
Pueschel SM, Reed RB, Cronk CE, Goldstein BI. 5-hydroxytryptophan and pyridoxine. Their effects in young children with Down's syndrome. Am J Dis Child 1980;134:838-44. View abstract.
Ribeiro CA. L-5-Hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. Headache 2000;40:451-6. View abstract.
Rondanelli M, Klersy C, Iadarola P, et al. Satiety and amino-acid profile in overweight women after a new treatment using a natural plant extract sublingual spray formulation. Int J Obes (Lond) 2009;33:1174-1182. View abstract.
Rondanelli M, Opizzi A, Faliva M, Bucci M, Perna S. Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration. Eat Weight Disord 2012;17(1):e22-8. View abstract.
Rousseau JJ. Effects of a levo-5-hydroxytryptophan-dihydroergocristine combination on depression and neuropsychic performance: a double-blind placebo-controlled clinical trial in elderly patients. Clin Ther 1987;9:267-72. View abstract.
Santucci M, Cortelli P, Rossi PG, Baruzzi A, Sacquegna T. L-5-hydroxytryptophan versus placebo in childhood migraine prophylaxis: a double-blind crossover study. Cephalalgia 1986;6:155-7. View abstract.
Sarzi Puttini P, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res 1992;20:182-9. View abstract.
Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002;(1):CD003198. View abstract.
Shell W, Bullias D, Charuvastra E, et al. A randomized, placebo-controlled trial of an amino acid preparation on timing and quality of sleep. Am J Ther 2010;17:133-9. View abstract.
Sicuteri F. 5-hydroxytryptophan in the prophylaxis of migraine. Pharmacological Research Communications 1972;4:213-218.
Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58:130-3. View abstract.
Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med 1980;303:782-7. View abstract.
Takahashi S, Kondo H, Kato N. Effect of l-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effect in depressed patients. J Psychiatr Res 1975;12:177-87. View abstract.
Titus F, Dávalos A, Alom J, Codina A. 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine. Randomized clinical trial. Eur Neurol 1986;25:327-9. View abstract.
Trouillas P, Brudon F, Adeleine P. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan: a double-blind study with quantified data processing. Arch Neurol 1988;45:1217-22. View abstract.
Trouillas P, Serratrice G, Laplane D, et al. Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study. Arch Neurol 1995;52:456-60. View abstract.
U. S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements. Information Paper on L-Tryptophan and 5-hydroxy-L-tryptophan, February 2001.
U.S. Food and Drug Administration Pharmacy Compounding Advisory Committee meeting June 17-18, 2015. Available at: www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm455276.pdf (accessed 8/21/15).
U.S. Food and Drug Administration. Impurities confirmed in dietary supplement 5-hydroxy-L-tryptophan. FDA Talk Paper, August 31, 1998; T98-48.
U.S. Food and Drug Administration. Orphan drug designations and approvals. Available at: www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm (accessed 8/20/2015).
van Hiele LJ. l-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with 'therapy-resistant' depressions. Neuropsychobiology 1980;6:230-40. View abstract.
van Praag HM, Korf J, Dols LC, Schut T. A pilot study of the predictive value of the probenecid test in application of 5-hydroxytryptophan as antidepressant. Psychopharmacologia 1972;25:14-21. View abstract.
Weise P, Koch R, Shaw KN, Rosenfeld MJ. The use of 5-HTP in the treatment of Down's syndrome. Pediatrics 1974;54(2)165-8. View abstract.
Wessel K, Hermsdörfer J, Deger K, et al. Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases. Arch Neurol 1995;52:451-5. View abstract.